ArticleIntractable & rare diseases research2025
Rare disease publishing trends worldwide and in China: A CiteSpace-based bibliometric study.
Article in Intractable & rare diseases research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Visualization analysis of the use of traditional Chinese medicine in the diagnosis and treatment of rare diseases in mainland China based on CiteSpace.Intractable & rare diseases research · 2026Article
- A bibliometric approach to worldwide scientific production of familial hypophosphataemic rickets in Scopus (2000-2022).Orphanet journal of rare diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to understand research trends, determine frontier topics, and explore the developments in and the differences between research conducted in China and the rest of the world. We analyzed the research status of rare diseases in China and globally over the past decade using bibliometric methods. We focused on rare disease literature indexed in the Web of Science (WoS) and China National Knowledge Infrastructure (CNKI) databases from January 2013 to December 2023. We selected studies based on inclusion and exclusion criteria. CiteSpace 6.1.R6 software were used to prepare knowledge graphs and perform comparative analyses of authors, institutions, content, and hot topics between both databases. A total of 10,754 articles from the WoS and 969 from the CNKI met the inclusion criteria. In the past 10 years, the diagnosis and treatment of rare diseases have been a common research focus in both China and the world. China has emphasized more on "orphan drugs". "Genes" and "management" were focused globally. The United States had the greatest number of publications. China ranks high in terms of publication volume and institutional ranking. Research interest in rare diseases has gradually increased worldwide, with European and American countries maintaining a leading position. China has made significant contributions. China's research is lagging compared to global trends, lacking collaboration with other countries. The diagnosis and treatment of rare diseases remain central themes, whereas genetic research, artificial intelligence, and sociological studies on rare disease populations are emerging as hot topics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.